p-EGFR Antibody (3F2): sc-57544

p-EGFR Antibody (3F2) is a mouse monoclonal IgG1 antibody that detects epidermal growth factor receptor (EGFR) in mouse, rat, human, and canine samples through applications such as western blotting (WB) and immunoprecipitation (IP). anti-EGFR antibody (3F2) is raised against a synthetic phosphopeptide of EGFR of human origin to specifically recognize phosphorylated forms of EGFR, which is crucial for understanding cell signaling pathways that regulate cell growth and differentiation. EGFR is primarily located on the cell surface, where EGFR functions as a receptor for epidermal growth factors, mediating critical cellular responses upon ligand binding. This localization allows EGFR to initiate signaling cascades that influence various physiological processes, including cell proliferation, survival, and migration. Dysregulation of EGFR signaling is implicated in numerous cancers, making EGFR an important target for therapeutic intervention. Phosphorylation of specific tyrosine residues on EGFR, such as Tyr 1092 and Tyr 1173, is essential for activation and subsequent downstream signaling, highlighting the importance of monitoring these modifications in research and clinical settings. EGFR monoclonal antibody (3F2) enables researchers to gain insights into the functional status of EGFR and involvement in disease mechanisms, thereby advancing understanding of targeted therapies in oncology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-EGFR Antibody (3F2) References:

1. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.  |  Cunningham, MP., et al. 2005. Int J Oncol. 27: 317-25. PMID: 16010411
2. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.  |  Magkou, C., et al. 2008. Breast Cancer Res. 10: R49. PMID: 18522728
3. Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer.  |  An, SJ., et al. 2012. Exp Ther Med. 4: 226-230. PMID: 23139712
4. Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas.  |  Monteiro, L., et al. 2014. Oral Dis. 20: 178-85. PMID: 23464360
5. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.  |  Di Lorenzo, G., et al. 2013. J Transl Med. 11: 161. PMID: 23819610
6. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling.  |  Pidugu, VK., et al. 2019. Oncogene. 38: 3232-3247. PMID: 30626937
7. The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR.  |  Tan, B., et al. 2020. Cancer Cell Int. 20: 458. PMID: 32963499
8. Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.  |  Rai, A., et al. 2021. Front Endocrinol (Lausanne). 12: 708111. PMID: 34295309
9. Estrogen alleviates post-traumatic osteoarthritis progression and decreases p-EGFR levels in female mouse cartilage.  |  Lu, Z., et al. 2022. BMC Musculoskelet Disord. 23: 685. PMID: 35854298
10. In Situ Hybridization (ISH) Combined with Immunohistochemistry (IHC) for Co-detection of EGFR RNA and Phosphorylated EGFR Protein in Lung Cancer Tissue.  |  Oliver, A., et al. 2023. Methods Mol Biol. 2593: 221-232. PMID: 36513934

The preferred EGFR antibody is EGFR Antibody (528): sc-120.